A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic Rhinitis

NCT05692154 | Completed Phase 3 Results FDA Drug

• 2 other identifiers: LPS17180U1111-1278-3949
• Study Type: interventional
• Target: 95
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a proof-of-concept study to demonstrate if a daily dose of a 2-days pre-treatment of Fexofenadine 180mg is effective in alleviating the AR symptoms and to assess the additional benefit to the patient in terms of preventing Allergic Rhinitis (AR) symptoms. The total study duration per participant is expected at least 4 months, depending on the timing of the screening visit. 5 visits are planned, screening, confirmation inclusion challenge, randomization visit, challenge and end of study visit.

Conditions

Seasonal Allergic Rhinitis

Outcome Measures

Primary Outcomes (1)

• Area Under Curve (AUC) of the Total Nasal Symptoms Score (TNSS-3)

  TNSS-3=composite score calculated as sum of rhinorrhea, sneezing, and nasal itching scores (TNSS-3: scale of each symptom is scored from 0 to 3), where 0 indicates no symptoms, a score of 1 for mild symptoms that are easily tolerated, 2 for awareness of symptoms which are bothersome but tolerable and 3 is reserved for severe symptoms that are hard to tolerate and interfere with daily activity. Individual scores were collected in e-diary. AUC of TNSS from time of the first observation to time of the last observation (AUC \[0-6 hr\]) was calculated by using the linear trapezoid method. Trapezoidal rule involves dividing the area into a number of strips of equal width. Then, approximating the area of each strip by the area of the trapezium formed when a chord replaces upper end. Sum of these approximations gives final numerical result of area under the curve. AUC range: Arm A=0.0-43.5; Arm B=2.1-39.9.

  From 0 hour to 6 hours at Day 4

Secondary Outcomes (6)

• AUC of Total Ocular Symptoms Score (TOSS) (H0-H6 at Day 4)

  From 0 hour to 6 hours at Day 4

• AUC of Total Nasal Symptoms Score (TNSS-3) (H0-H12 at Day 4)

  From 0 hour to 12 hours at Day 4

• AUC of Total Ocular Symptoms Score (TOSS) (H0-H12 at Day 4)

  From 0 hour to 12 hours at Day 4

• AUC of Total Nasal Symptoms Score (TNSS-3) (Day 1 to Day 4)

  From randomization (Day 1) to Day 4

• AUC of Total Ocular Symptoms Score (TOSS) (Day 1 to Day 4)

  From randomization (Day 1) to Day 4

Study Arms (2)

Arm A (active-active)

EXPERIMENTAL

Two days of pre-treatment with Fexofenadine 180 mg each day in the morning on Day 2 and Day 3, then Fexofenadine180 mg after the pollen challenge on Day 4.

Drug: Fexofenadine

Arm B (placebo-active)

EXPERIMENTAL

Two days of pre-treatment with tablet of matching placebo each day in the morning on Day 2 and Day 3, then Fexofenadine180 mg after the pollen challenge on Day 4.

Drug: Placebo

Interventions

Fexofenadine DRUG

Fexofenadine oral tablet

Arm A (active-active)

Placebo DRUG

Fexofenadine matching placebo oral tablet

Arm B (placebo-active)

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants are eligible to be included in the study only if all of the following criteria apply:
• Participant is willing to provide written informed consent.
• Adult participants (18 to 80 years old) suffering from seasonal allergic rhinitis (SAR) provoked by Ragweed pollen.
• Participants having a total nasal symptom score (TNSS)-3 ≥4 (with 3 nasal symptoms) at first pollen challenge at Visit 2.
• Having a 2-year history of SAR with Positive skin prick test to Ragweed allergen at screening (with a wheal diameter at least 3 mm larger than that produced by the negative control).

You may not qualify if:

• History of anaphylaxis to Ragweed pollen History of asthma or exacerbations in the past 12 months requiring regular inhaled corticosteroids for greater than 4 weeks per year, any oral corticosteroid usage, any emergency department visit for asthma or any asthma-related hospitalization. Mild asthmatics treated only with pro re nata short-acting β2agonists, less than 2 doses per week can be enrolled.
• History of chronic sinusitis, defined as a sinus symptoms lasting greater than 12 weeks that includes 2 or more major factors or 1 major factor and 2 minor factors. Major factors are defined as facial pain or pressure, nasal obstruction or blockage, nasal discharge or purulence or discolored postnasal discharge, purulence in nasal cavity, or impaired or loss of smell. Minor factors are defined as headache, fever, halitosis, fatigue, dental pain, cough, and ear pain, pressure, or fullness.
• History of systemic disease affecting the immune system such as autoimmune diseases, immune complex disease, or immunodeficiency, where, in the opinion of the study physician, participation in the trial would pose a risk or significant effect on the immune system.
• Presence or history of drug hypersensitivity to fexofenadine and/or its excipients.
• Participants unable to stop the following forbidden treatments/nutriments prior to pollen challenge:
• Antihistamines: within 3 days for first-generation antihistamines, within 2 days for second-generation antihistamines.
• Intranasal or inhaled corticosteroids: 7 days.
• Ocular, intranasal, or inhaled sodium cromoglycate: 14 days.
• High doses of systemic corticosteroids: 30 days.
• Leukotriene antagonists: 30 days.
• Intranasal or systemic decongestants: 3 days.
• Tricyclic antidepressants: 7 days.
• Any citrus fruits (grapefruit, orange, etc.) or their juices, as well as all fruit juices: 5 days.
• Aluminum-and-magnesium containing antacids: 7 days.
• Omalizumab/dupilumab: within 6 months

Sponsors & Collaborators

• Opella Healthcare Group SAS, a Sanofi Company: lead

Study Sites (1)

Investigational Site Number : 1240001

Kingston, Ontario, K7L 2V7, Canada

Location

Related Links

• LPS17180 Plain Language Results Summary

MeSH Terms

Conditions

Rhinitis, Allergic, Seasonal

Interventions

fexofenadine

Condition Hierarchy (Ancestors)

Rhinitis, Allergic; Rhinitis; Nose Diseases; Respiratory Tract Diseases; Respiratory Hypersensitivity; Otorhinolaryngologic Diseases; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Results Point of Contact

• Title: Trial Transparency Team
• Organization: Sanofi aventis recherche & développement

Contact-US@sanofi.com

800-633-1610

Study Officials

• Clinical Sciences & Operations

  Sanofi

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 11, 2023
• First Posted: January 20, 2023
• Study Start: January 23, 2023
• Primary Completion: March 14, 2023
• Study Completion: March 14, 2023
• Last Updated: September 9, 2025
• Results First Posted: May 16, 2024

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will share

Locations

CA (1)